EVALUATION OF THE IMMUNOMODULATORY EFFECTS OF THE MACROLIDE ANTIBIOTIC, CLARITHROMYCIN, IN FEMALE B6C3F1 MICE: A 28-DAY ORAL GAVAGE STUDY

Autor:	N. A. Karrow, J. A. McCay, R. D. Brown, D. L. Musgrove, D. R. Germolec, K. L. White, Kimber L. White
Rok vydání:	2001
Předmět:	Cellular immunity medicine.drug_class Health Toxicology and Mutagenesis Antibiotics Mice Inbred Strains Spleen Biology Lymphocyte Activation Toxicology Mice Immune system Adjuvants Immunologic Immunity Clarithromycin Toxicity Tests medicine Animals Antibody-Producing Cells Intubation Gastrointestinal Pharmacology Chemical Health and Safety Innate immune system Dose-Response Relationship Drug Macrophages Body Weight Public Health Environmental and Occupational Health Organ Size General Medicine biochemical phenomena metabolism and nutrition Anti-Bacterial Agents Blood Cell Count Killer Cells Natural medicine.anatomical_structure Immunoglobulin M Antibody Formation Immunology Humoral immunity Female T-Lymphocytes Cytotoxic medicine.drug
Zdroj:	Drug and Chemical Toxicology. 24:19-37
ISSN:	1525-6014 0148-0545
DOI:	10.1081/dct-100103083
Popis:	The macrolide antibiotic, clarithromycin, is used extensively to treat bacterial infections associated with pneumonia, duodenal ulcers, and the advanced stages of human immunodeficiency viral (HIV) infection. In addition to its antimicrobial properties, several studies have indicated that clarithromycin also has anti-inflammatory and immunomodulatory properties. In this study, clarithromycin's immunomodulatory properties were evaluated using female B6C3F1 mice and a panel of immune assays that were designed to evaluate potential changes in innate, and acquired cellular and humoral immune responses. Female B6C3F1 mice were treated daily by gavage with clarithromycin (0, 125, 250, and 500 mg/kg) for 28 days then evaluated for immunomodulation. Minimal immunological changes were observed after 28 days of treatment. A slight increase in the number of spleen antibody-forming cells was observed at the 250 mg/kg treatment level, but not at other doses. Serum IgM levels were unaffected by the clarithromycin treatment. A significant increase in the number of splenic macrophages was also observed in mice treated with 125 mg/kg of clarithromycin, but this increase was not observed at the other treatment levels. Innate and cell-mediated immunity, as measured by natural killer cell activity, and mixed leukocyte and cytotoxic T cell response, respectively, were unchanged following treatment with clarithromycin. These results suggest that the immune system is not a target for clarithromycin at doses of 500 mg/kg or below.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e9b4f86cac9b4541cfa11d7513d3774 https://doi.org/10.1081/dct-100103083 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.